Ivonescimab and chemo for EGFR lung cancer spread to the brain lining
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose lung cancer has spread to the tissues around the brain and spinal cord (leptomeningeal metastasis) and who have already tried a targeted therapy that stopped working. The goal is to see if this combo can control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have non-small cell lung cancer with an EGFR gene mutation that can be targeted by certain pills.
- Your cancer must have spread to the leptomeninges (the tissues around the brain and spinal cord).
- You must have already tried an EGFR-targeted pill (like erlotinib, gefitinib, afatinib, or osimertinib) and it stopped working.
- Your blood counts, liver, kidney, and clotting function should be good enough to receive treatment.
- If you are a woman who could become pregnant, you must have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
This trial tests a new combination of an immunotherapy drug (AK112) with standard chemotherapy as the first treatment for people with a certain type of lung cancer that has spread to the brain. It may help control the cancer by boosting your immune system to fight it, and the study will check how well it works and how safe it is.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Hear when a new Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.